MXCT · Maxcyte, Inc.
$1.32
-0.07 (-5.04%)
At close · Aug 14
Market Cap
$136.23M
Shares
103.21M
Maxcyte, Inc. Earnings Call Transcripts
Every quarterly earnings call for Maxcyte, Inc. (MXCT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲5%
$10.64M
−$6.43M
'22 Q3
22-11-09
▲22.4%
$12.42M
−$4.81M
'22 Q4
23-03-06
▼26%
$8.58M
−$10.88M
'23 Q1
23-05-10
▼5.9%
$9.04M
−$10.51M
'23 Q2
23-08-09
▼24.8%
$8.00M
−$11.25M
'23 Q3
23-11-08
▲26.1%
$15.66M
−$5.28M
'23 Q4
24-03-12
▲32.3%
$11.34M
−$9.53M
'24 Q1
24-05-07
▲15.3%
$10.43M
−$9.38M
'24 Q2
24-08-06
▲2%
$8.16M
−$11.56M
'24 Q3
24-11-06
▼44.5%
$8.69M
−$10.60M
'24 Q4
25-01-13
▼8.4%
$10.39M
−$10.26M
'25 Q1
25-05-07
▼18.4%
$8.51M
−$12.36M
'25 Q2
25-08-06
▼16.4%
$6.83M
−$12.42M
'25 Q3
25-11-05
▼7.1%
$9.65M
−$4.75M
'26 Q1
26-05-12
▼16%
$7.30M
−$9.60M
'25 Q4
26-05-12
LATEST
▼14.5%
$7.27M
−$8.87M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
Maxcyte, Inc. Q2 FY2026 Earnings Call
Revenue
$7.27M
▼ 14.5% YoY Diluted EPS
$-0.08
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-05-12
Maxcyte, Inc. Q4 FY2025 Earnings Call
Balanced tone
2026 Revenue Guidance
Cell Therapy Market Outlook
ExPERT DTX Product Launch
Revenue
$7.30M*
▼ 16% YoY Gross margin
77.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY26 · Q1
2026-05-12
Maxcyte, Inc. Q1 FY2026 Earnings Call
Positive tone
SPL Partner Pipeline and Registrational Programs
Core Revenue and SPL Program Mix
SeQure Off-Target Assay Services
Revenue
$9.65M
▼ 7.1% YoY Diluted EPS
$-0.04
Gross margin
83.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q3
2025-11-05
Maxcyte, Inc. Q3 FY2025 Earnings Call
Positive tone
SPL Partnership Pipeline
Long-Term Value and Growth Strategy
Gross Margin and Product Mix
Revenue
$6.83M
▼ 16.4% YoY Diluted EPS
$-0.12
Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Maxcyte, Inc. Q2 FY2025 Earnings Call
Cautious tone
SeQure Dx integration
Clinical program progress and pivotal studies
CASGEVY commercial momentum (Vertex)
Revenue
$8.51M
▼ 18.4% YoY Diluted EPS
$-0.12
Gross margin
82.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Maxcyte, Inc. Q1 FY2025 Earnings Call
Positive tone
SeQure Dx integration and revenue
Cell and gene therapy market trends
SPL portfolio and pipeline
Revenue
$10.39M
▼ 8.4% YoY Diluted EPS
$-0.10
Gross margin
85.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
Maxcyte, Inc. Q4 FY2024 Earnings Call
Positive tone
SeQure Dx Acquisition and Integration
2025 Guidance and Quarterly Cadence
SPL Portfolio Expansion
Revenue
$8.69M*
▼ 44.5% YoY Gross margin
73.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Maxcyte, Inc. Q3 FY2024 Earnings Call
Confident tone
SPL Pipeline Growth & New Signings
Core Revenue & 2024 Guidance Increase
CASGEVY Commercial Milestone Opportunity
Revenue
$8.16M
▲ 2% YoY Diluted EPS
$-0.11
Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Maxcyte, Inc. Q2 FY2024 Earnings Call
Positive tone
Cell therapy market opportunity
CASGEVY / Vertex commercial launch
VLX portfolio realignment
Revenue
$10.43M
▲ 15.3% YoY Diluted EPS
$-0.09
Gross margin
85.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Maxcyte, Inc. Q1 FY2024 Earnings Call
Revenue
$11.34M
▲ 32.3% YoY Gross margin
87.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
Maxcyte, Inc. Q4 FY2023 Earnings Call
Positive tone
Strategic Platform Licenses (SPL) portfolio growth
CASGEVY commercial launch and royalties
Leadership transition and strategic priorities
Revenue
$15.66M*
▲ 26.1% YoY Gross margin
90.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Maxcyte, Inc. Q3 FY2023 Earnings Call
Revenue
$8.00M
▼ 24.8% YoY Diluted EPS
$-0.11
Gross margin
90.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Maxcyte, Inc. Q2 FY2023 Earnings Call
Revenue
$9.04M
▼ 5.9% YoY Diluted EPS
$-0.10
Gross margin
84.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Maxcyte, Inc. Q1 FY2023 Earnings Call
Revenue
$8.58M
▼ 26% YoY Diluted EPS
$-0.11
Gross margin
88.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-06
Maxcyte, Inc. Q4 FY2022 Earnings Call
Revenue
$12.42M*
▲ 22.4% YoY Gross margin
87.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Maxcyte, Inc. Q3 FY2022 Earnings Call
Revenue
$10.64M
▲ 5% YoY Diluted EPS
$-0.06
Gross margin
87.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Maxcyte, Inc. Q2 FY2022 Earnings Call
Revenue
$9.61M
▲ 35.2% YoY Diluted EPS
$-0.08
Gross margin
88.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Maxcyte, Inc. Q1 FY2022 Earnings Call
Revenue
$11.59M
▲ 78.4% YoY Diluted EPS
$-0.04
Gross margin
90.8%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Maxcyte, Inc. Q4 FY2021 Earnings Call
Revenue
$10.15M*
Gross margin
87.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Maxcyte, Inc. Q3 FY2021 Earnings Call
Revenue
$10.14M
▲ 49.9% YoY Diluted EPS
$-0.03
Gross margin
90.7%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-09-17
Maxcyte, Inc. Q2 FY2021 Earnings Call
Revenue
$7.11M
▲ 38% YoY Diluted EPS
$-0.05
Gross margin
89.0%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–21 of 21 earnings calls